Kura Oncology (KURA) Convertible Debt (2014)

Kura Oncology (KURA) reported Convertible Debt of $500000.0 for Q4 2014.

Kura Oncology (KURA) has 1 years of Convertible Debt data on file, last reported at $500000.0 in Q4 2014.

  • Quarterly Convertible Debt changed N/A year-over-year to $500000.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $500000.0 (changed N/A YoY) and the FY2014 annual result came in at $500000.0, changed N/A from the prior year.
  • Convertible Debt held at $500000.0 in Q4 2014 per KURA's latest filing.
  • Across five years, Convertible Debt topped out at $500000.0 in Q4 2014 and bottomed at $500000.0 in Q4 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2014 500,000.00